Special Issues

Special Issue Title: Prevention of Cardiovascular Diseases

· Print Special Issue Flyer

· Deadline for manuscript submissions:  1 November 2020

Special Issue Editor

Guest Editor

       Prof. Dr.  Michael D. Shapiro

       Fred M. Parrish Professor of Cardiology and Molecular Medicine
       Wake Forest School of Medicine

Website | E-Mail

Interests: Preventive cardiology; Atherosclerosis; lipoprotein metabolism; PCSK9 physiology; Atherosclerosis imaging

Special Issue Information

Dear Colleagues,

We are in the midst of a revolution in the prevention and management of cardiovascular disease, with the emergence of new drugs and new targets associated with improved cardiovascular outcomes. At the same time, advances in risk assessment, including novel biomarkers, genetics, and noninvasive subclinical atherosclerosis imaging represent major advances that will be implemented more widely in the coming years. Issues related to primary and secondary prevention are becoming increasing complex, and more and more patients are seeking specialized advice on cardiovascular risk assessment and management. This issue of Reviews in Cardiovascular Medicine tackles these bold issues and provides a glimpse into the next frontiers in prevention of cardiovascular disease.

Prof. Dr.  Michael D. Shapiro

Guest Editor


Manuscript Submission Information

Manuscripts should be submitted online at https://rcm.imrpress.org by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reviews in Cardiovascular Medicine is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1950. Submitted papers should be well formatted and use good English.


Preventive cardiology; Atherosclerotic cardiovascular disease; Risk assessment; Biomarkers; Atherosclerosis imaging; Genetics


Share This Special Issue


Please wait a minute...
For Selected: Toggle Thumbnails
Role of coronary microvascular dysfunction in heart failure with preserved ejection fraction
Francesco Tona, Roberta Montisci, Laura Iop, Giovanni Civieri
Reviews in Cardiovascular Medicine    2021, 22 (1): 97-104.   DOI: 10.31083/j.rcm.2021.01.277
Abstract524)   HTML79)    PDF(pc) (771KB)(948)       Save
Heart failure with preserved ejection fraction (HFpEF) is one of the greatest unmet needs in modern medicine. The lack of an appropriate therapy may reflect the lack of an accurate comprehension of its pathophysiology. Coronary microvascular rarefaction in HFpEF was first hypothesized in an autopsy study that showed how HFpEF patients had lower microvascular density and more myocardial fibrosis than control subjects. This was later confirmed in vivo when it was noted that HFpEF is associated with reduced myocardial flow reserve (MFR) at single photon emission computed tomography (SPECT) and that coronary microvascular dysfunction may play a role in HFpEF disease processes. HFpEF patients were found to have lower coronary flow reserve (CFR) and a higher index of microvascular resistance (IMR). What is the cause of microvascular dysfunction? In 2013, a new paradigm for the pathogenesis of HFpEF has been proposed. It has been postulated that the presence of a proinflammatory state leads to coronary microvascular endothelial inflammation and reduced nitric oxide bioavailability, which ultimately results in heart failure. Recently, it has also been noted that inflammation is the main driver of HFpEF, but via an increase in inducible nitric oxide synthase (iNOS) resulting in a decrease in unfolded protein response. This review summarizes the current evidence on the etiology of coronary microvascular dysfunction in HFpEF, focusing on the role of inflammation and its possible prevention and therapy.
Related Articles | Metrics

Current Issue

  • Volume 22, Issue 3